ENHANCE Win: Single 600mg BRIUMVI Infusion Matches Two-Dose Regimen
TGTX has more than doubled off its 52-week low of $26.76.
Summary
The Phase 3b ENHANCE trial met its primary endpoint: a single 600 mg BRIUMVI infusion matched the approved two-infusion regimen, with comparable infusion reactions and no severe cases. That is the real news here — a one-infusion label could simplify dosing and sharpen BRIUMVI's competitive edge. It sits alongside Q3 revenue of $259.9 million, up 61%, profit of $55.5 million, and 2026 revenue guidance raised to about $1 billion, all reported November 9th. The company also finished enrollment in the subcutaneous ublituximab Phase 3 study, with topline expected around the end of 2026 or in the first quarter of 2027. Evercore ISI kept Outperform but trimmed its price target to $71 from $73.
At the time of this announcement, TGTX was trading at $63.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $26.76 to $68.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.